Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224546 | 0.86 | KDM4C (0.38) | GHSRNR1H3NR1H2GRM5GPR119 | |
| SCHEMBL2226709 | 0.82 | GRM5 (0.39) | NR1H3NR1H2GRM5GPR119 | |
| SCHEMBL2225115 | 0.82 | HTR6 (0.41) | FFAR4HTR6GPR119 | |
| SCHEMBL2227962 | 0.79 | GRM5 (0.38) | GHSRNR1H3NR1H2GRM5GPR119 | |
| SCHEMBL2228079 | 0.76 | ALDH1A1 (0.41) | GHSRGRM5 | |
| SCHEMBL2227389 | 0.76 | GRM5 (0.41) | NR1H3NR1H2GRM5 | |
| SCHEMBL2226108 | 0.75 | GRM5 (0.40) | NR1H3NR1H2GRM5GPR119 | |
| SCHEMBL2223788 | 0.73 | NR1H2 (0.38) | NR1H3NR1H2GRM5GPR119 | |
| SCHEMBL6895214 | 0.72 | GRM5 (0.40) | NR1H3NR1H2GRM5GPR119 | |
| SCHEMBL2225594 | 0.70 | USP30 (0.43) | NR1H3NR1H2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368257-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368257-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9115147-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115147-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2792678-A1 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2516446-B1 | SUBSTITUTED HEXAHYDROCHROMENO[3,4-B]PYRROLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR (5-HT) FAMILY | CEPHALON INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2011087713-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368257-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP11B2, CYP11B1, CYP4A11 | FFAR4 976/4885GHSR 1447/4885HTR6 874/4885 |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP11B2, CYP11B1, CYP4A11 | FFAR4 976/4885GHSR 1447/4885HTR6 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.